TY - JOUR
T1 - Evaluation of organic anion transporter 1A2-knock-in mice as a model of human blood-brain barrier
AU - Sano, Yamato
AU - Mizuno, Tadahaya
AU - Mochizuki, Tatsuki
AU - Uchida, Yasuo
AU - Umetsu, Mina
AU - Terasaki, Tetsuya
AU - Kusuhara, Hiroyuki
N1 - Funding Information:
This study was supported by a grant-in-aid for Research on Development of New Drugs from the Japan Agency for Medical Research and Development, AMED [16ak0101030j003] and for Scientific Research (B) [26293032] from the Japan Society for the Promotion of Science. 1Y.S. and T.M. contributed equally to this work. https://doi.org/10.1124/dmd.118.081877. s This article has supplemental material available at dmd.aspetjournals.org.
Publisher Copyright:
© 2018 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2018/11
Y1 - 2018/11
N2 - The present study aimed to establish a humanized mouse model with which to explore OATP1A2-mediated transcellular transport of drug substrates across the blood-brain barrier (BBB) and to evaluate the usefulness of the humanized mice in preclinical studies. Sulpiride, amisulpride, sultopride, and triptans were used as probes to discriminate OATP1A2 and Oatp1a4. We generated a mouse line humanized for OATP1A2 by introducing the coding region downstream of the Oatp1a4 promoter using the CRISPR/Cas9 technique. In the mice generated, OATP1A2 mRNA in the brain was increased corresponding to disappearance of Oatp1a4. OATP1A2 was localized on both the luminal and abluminal sides of the BBB. Unfortunately, study in vivo employing sulpiride, sumatriptan, and zolmitriptan as probes did not indicate any difference in their brain-to-plasma ratio between the control and humanized mice. Quantitative targeted absolute proteomic analysis of the BBB fraction from the humanized mice revealed that almost all analyzed transporters and membrane proteins were expressed at similar levels to those in controlmice. The quantitative levels of OATP1A2 differed depending on the peptide quantified, which suggests that incomplete translation or posttranslational modification may occur. The blood-to-brain transport of zolmitriptan, determined by brain perfusion in situ, was 1.6-fold higher in the humanized mice than in the controls, whereas that of sulpiride was not significantly changed. To our knowledge, we established a mouse line humanized for a BBB uptake transporter for the first time. Unfortunately, because of limited impact, there is still room for improvement of the model system.
AB - The present study aimed to establish a humanized mouse model with which to explore OATP1A2-mediated transcellular transport of drug substrates across the blood-brain barrier (BBB) and to evaluate the usefulness of the humanized mice in preclinical studies. Sulpiride, amisulpride, sultopride, and triptans were used as probes to discriminate OATP1A2 and Oatp1a4. We generated a mouse line humanized for OATP1A2 by introducing the coding region downstream of the Oatp1a4 promoter using the CRISPR/Cas9 technique. In the mice generated, OATP1A2 mRNA in the brain was increased corresponding to disappearance of Oatp1a4. OATP1A2 was localized on both the luminal and abluminal sides of the BBB. Unfortunately, study in vivo employing sulpiride, sumatriptan, and zolmitriptan as probes did not indicate any difference in their brain-to-plasma ratio between the control and humanized mice. Quantitative targeted absolute proteomic analysis of the BBB fraction from the humanized mice revealed that almost all analyzed transporters and membrane proteins were expressed at similar levels to those in controlmice. The quantitative levels of OATP1A2 differed depending on the peptide quantified, which suggests that incomplete translation or posttranslational modification may occur. The blood-to-brain transport of zolmitriptan, determined by brain perfusion in situ, was 1.6-fold higher in the humanized mice than in the controls, whereas that of sulpiride was not significantly changed. To our knowledge, we established a mouse line humanized for a BBB uptake transporter for the first time. Unfortunately, because of limited impact, there is still room for improvement of the model system.
UR - http://www.scopus.com/inward/record.url?scp=85055078490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055078490&partnerID=8YFLogxK
U2 - 10.1124/dmd.118.081877
DO - 10.1124/dmd.118.081877
M3 - Article
C2 - 30154106
AN - SCOPUS:85055078490
SN - 0090-9556
VL - 46
SP - 1767
EP - 1775
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 11
ER -